Favipiravir Is Associated With Reduced 28‐Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score–Matched Study
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71029 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Jiankang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Pyrazines, Antiviral Agents, Severe Fever with Thrombocytopenia Syndrome, Amides. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Project of Lu'an Science and Technology Scheme.
Abstract (Originalsprache)
This study aimed to evaluate the efficacy of add‐on favipiravir to standard ribavirin therapy in reducing 28‐day mortality among patients with SFTS and to identify clinical subgroups that may derive greater benefit. This multicenter retrospective study included adults with laboratory‐confirmed SFTS from four hospitals (2022–2025). All patients received standard ribavirin therapy, while patients in the FPV group additionally received favipiravir at admission. Propensity score matching ensured balance in baseline characteristics. Survival was analyzed using Kaplan–Meier curves and Cox models with subgroup interaction analyses. Among 1199 eligible patients, the 28‐day mortality was 20.6%. The FPV group showed lower 28‐day mortality than the non‐FPV group (14.1% vs. 24.5%). FPV treatment was associated with lower 28‐day mortality across all baseline viral load categories, with the most pronounced association observed in patients with low viral load (< 10 5 copies/mL), and a weaker but still significant association in those with high viral load (≥ 10 7 copies/mL). A significant association was also observed in patients with onset‐to‐admission interval ≥ 5 days and in those aged < 70 years. A trend toward lower mortality was also observed in patients with an onset‐to‐admission interval < 5 days and in those aged ≥ 70 years, although the associations were not statistically significant. FPV treatment was associated with reduced mortality regardless of corticosteroid or intravenous immunoglobulin use. In this study, FPV therapy was associated with reduced 28‐day mortality regardless of baseline viral load or the interval of onset‐to‐admission. These findings support initiating FPV therapy promptly after admission without waiting for viral load results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Infectious Diseases, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
- Department of Infectious Diseases, Chaohu Hospital of Anhui Medical University, Chaohu, Anhui, China.
- Department of Infectious Diseases, Anqing Municipal Hospital, Anqing, Anhui, China.
ORCID-Profile: Jiankang Zhang, Jianguo Rao, Lifen Hu
Förderung
- National Natural Science Foundation of China
- Project of Lu'an Science and Technology Scheme
Zitieren
APA
Zhang, J., Zhang, C., Pan, Z. P., Rao, J., Deng, X., Wei, L., Ding, X., Ye, Y., & Hu, L. (2026). Favipiravir Is Associated With Reduced 28‐Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score–Matched Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.71029
Vancouver
Zhang J, Zhang C, Pan ZP, Rao J, Deng X, Wei L, et al. Favipiravir Is Associated With Reduced 28‐Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score–Matched Study. Journal of Medical Virology. 2026. doi:10.1002/jmv.71029
BibTeX
@article{Zhang2026,
author = {Zhang, Jiankang and Zhang, Chun and Pan, Zhi Ping and Rao, Jianguo and Deng, Xiangjun and Wei, Liangchen and Ding, Xiaobo and Ye, Ying and Hu, Lifen},
title = {Favipiravir Is Associated With Reduced 28‐Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score–Matched Study},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71029}
}
EUVIMED